Ephraim Heller

Ephraim Heller is a prolific inventor and entrepreneur, and the current CEO of SynAgile Corporation. SynAgile is developing new therapies for treatment of Parkinson's disease. In 1992, he was the co-founder and first CEO of TheraSense, which went public and was later sold to Abbott Labs for $1.2 billion. He was also co-founder, chairman and CEO of AngioScore and led the product development and FDA approval. AngioScore was acquired in 2014 for $230 million plus milestone payments. Prior to its acquisition, the company sold more than 300,000 AngioSculpt catheters in over 65 countries around the world. He was previously a Venture Partner at 7 Health Ventures. Heller holds an MBA from Yale School of Management and he has an AB in Physics from Harvard.